主要還是其對原株及變異株的有效性和相對低的副作用。另外，有迅速更新的潛能，以對付更糟的變異株。第三針在測試中

來源: fuz 於 2021-03-13 18:22:53 [] [博客] [舊帖] [給我悄悄話] 閱讀數 : (19039 bytes)
本帖於 2021-03-13 19:03:02 時間, 由普通用戶 fuz 編輯

Pfizer-BioNTech vaccine may neutralize Brazil variant, lab study

https://www.washingtonpost.com/nation/2021/03/09/coronavirus-covid-live-updates-us/


Why Pfizer thinks a booster of its Covid vaccine might work against new variants
https://www.statnews.com/2021/02/25/is-more-simply-better-why-pfizer-thinks-a-booster-of-its-covid-vaccine-might-work-against-new-variants/

 

how well COVID-19 vaccines work against the 3 most worrisome coronavirus variants 
https://www.businessinsider.com/covid-19-vaccines-efficacy-variants-south-africa-uk-brazil-2021-3

Once a slew of mutations makes a particular strain better at infecting people, deadlier, or more able to evade the antibodies generated from a vaccination or a previous infection, geneticists label it a variant of concern.

There are three of these: B.1.1.7, the variant initially spotted in the UK in September; P.1, which was discovered in December; and B.1.351, which was detected in samples from South Africa dating back to October.

 

  ORIGINAL VIRUS B.1.1.7 B.1.351 P.1
Pfizer-BioNTech 95% Same efficacy Reduced antibody levels Same efficacy
Moderna 94% Same efficacy Reduced antibody levels More data needed
J&J 72%* Same efficacy Reduced efficacy
(in South Africa trials)		 Reduced efficacy
(in Latin America trials)
AstraZeneca 60-90% Same efficacy Reduced efficacy Same efficacy
Sinovac 50% Same efficacy Reduced antibody levels Reduced antibody levels
Note: *In US trials. Average of 66% efficacy with South Africa and Latin America trials included.
請您先登陸，再發跟帖！